Trial Profile
A Randomized, Double Blind Phase II Proof-of-Concept Superiority Trial of Fosravuconazole 200 mg or 300 mg Weekly Dose Versus Itraconazole 400 mg Daily, All Three Arms in Combination With Surgery, in Patients With Eumycetoma in Sudan
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Apr 2020
Price :
$35
*
At a glance
- Drugs Fosravuconazole (Primary) ; Itraconazole
- Indications Mycetoma
- Focus Proof of concept; Therapeutic Use
- 21 Apr 2017 Status changed from not yet recruiting to recruiting.
- 28 Mar 2017 New trial record